Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates [Yahoo! Finance]
Puma Biotechnology Inc (PBYI)
Last puma biotechnology inc earnings: 2/20 04:07 pm
Check Earnings Report
US:NYSE Investor Relations:
pumabiotechnology.com/ir.html
Company Research
Source: Yahoo! Finance
In the year-ago quarter, the company had reported an adjusted loss of 7 cents. The above-adjusted earnings exclude the impact of stock-based compensation expense. Including the same, reported earnings per share were 26 cents in the fourth quarter of 2023 against a loss of 12 cents reported in the year-ago quarter. In the fourth quarter, total revenues were $72.2 million, which slightly missed the Zacks Consensus Estimate of $72.8 million. Revenues, however, increased around 9.9% year over year. Total revenues comprised net product sales of Nerlynx (neratinib), Puma Biotechnology's only marketed drug in the United States, and royalty revenues. Nerlynx is indicated for treating early-stage HER2-positive breast cancer. Shares of Puma Biotechnology were down 12.4% in after-hours trading on Feb 29 following the announcement of the earnings. The stock has rallied 38.2% in the past year against the industry's 4.6% decline. Image Source: Zacks Investment Research Quarter in Detail
Show less
Read more
Impact Snapshot
Event Time:
PBYI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBYI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBYI alerts
High impacting Puma Biotechnology Inc news events
Weekly update
A roundup of the hottest topics
PBYI
News
- Puma Biotechnology, Inc. (NASDAQ: PBYI) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Analysts Have Lowered Expectations For Puma Biotechnology, Inc. (NASDAQ:PBYI) After Its Latest Results [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology: A Story In Flux Heading Into Mid-2024 [Seeking Alpha]Seeking Alpha
- Puma Biotechnology, Inc. (NASDAQ: PBYI) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Puma Biotechnology, Inc. (NASDAQ: PBYI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
PBYI
Earnings
- 5/2/24 - Beat
PBYI
Analyst Actions
- 5/3/24 - HC Wainwright
PBYI
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/26/24 - Form DEFA14A
- PBYI's page on the SEC website